胶质母细胞瘤中失调的信号通路：分子机制与治疗靶点。
Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.
机构信息
The Vivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center at Houston, Medical School, Houston, Texas 77030, USA.
出版信息
Cancer Invest. 2012 Jan;30(1):48-56. doi: 10.3109/07357907.2011.630050.
Abstract
Glioblastoma multiforme (GBM) is the most malignant and aggressive type of brain tumor with an average life expectancy of less than 15 months. This is mostly due to the highly mutated genome of GBM, which is characterized by the deregulation of many key signaling pathways involving growth, proliferation, survival, and apoptosis. It is critical to explore novel diagnostic and therapeutic strategies that target these pathways to improve the treatment of malignant glioma in the future. This review summarizes the most common and important pathways that are highly mutated or deregulated in GBM and discusses potential therapeutic strategies targeting these pathways.
摘要
多形性胶质母细胞瘤（GBM）是最恶性和侵袭性的脑肿瘤，平均预期寿命不到 15 个月。这主要是由于 GBM 高度突变的基因组，其特征是涉及生长、增殖、存活和凋亡的许多关键信号通路的失调。探索针对这些通路的新型诊断和治疗策略对于改善恶性胶质瘤的治疗至关重要。本综述总结了 GBM 中高度突变或失调的最常见和最重要的通路，并讨论了针对这些通路的潜在治疗策略。
相似文献
1
Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.
Cancer Invest. 2012 Jan;30(1):48-56. doi: 10.3109/07357907.2011.630050.
2
Molecular pathways and potential therapeutic targets in glioblastoma multiforme.
Expert Rev Anticancer Ther. 2013 Nov;13(11):1307-18. doi: 10.1586/14737140.2013.852472.
3
Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date.
Cancer. 2015 Feb 15;121(4):502-16. doi: 10.1002/cncr.28968. Epub 2014 Sep 23.
4
SnapShot: glioblastoma multiforme.
Cancer Cell. 2012 May 15;21(5):710-710.e1. doi: 10.1016/j.ccr.2012.04.031.
5
The role of Myc and let-7a in glioblastoma, glucose metabolism and response to therapy.
Arch Biochem Biophys. 2015 Aug 15;580:84-92. doi: 10.1016/j.abb.2015.07.005. Epub 2015 Jul 4.
6
Transcription factors in glioblastoma - Molecular pathogenesis and clinical implications.
Biochim Biophys Acta Rev Cancer. 2022 Jan;1877(1):188667. doi: 10.1016/j.bbcan.2021.188667. Epub 2021 Dec 8.
7
Natural products as promising targets in glioblastoma multiforme: a focus on NF-κB signaling pathway.
Pharmacol Rep. 2020 Apr;72(2):285-295. doi: 10.1007/s43440-020-00081-7. Epub 2020 Mar 9.
8
Targeting metabolic remodeling in glioblastoma multiforme.
Oncotarget. 2010 Nov;1(7):552-62. doi: 10.18632/oncotarget.190.
9
Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Oncotarget. 2015 Sep 22;6(28):26192-215. doi: 10.18632/oncotarget.4613.
10
Harnessing the role of aberrant cell signaling pathways in glioblastoma multiforme: a prospect towards the targeted therapy.
Mol Biol Rep. 2024 Oct 19;51(1):1069. doi: 10.1007/s11033-024-09996-3.
引用本文的文献
1
Targeting TXN1 Induces G2M Phase Arrest and Apoptosis of Glioma Cells Through P38 MAPK Pathway.
Appl Biochem Biotechnol. 2025 Aug 20. doi: 10.1007/s12010-025-05341-x.
2
Nanocomposite biosensor tracks honokiol-induced oxidative stress dynamics in 3D hydrogel-cultured lung cancer cells.
Microsyst Nanoeng. 2025 Aug 14;11(1):154. doi: 10.1038/s41378-025-01016-z.
3
A Study on the Levels of Selected Proangiogenic Proteins in Human Tissues and Plasma in Relation to Brain Glioma.
Int J Mol Sci. 2025 May 16;26(10):4802. doi: 10.3390/ijms26104802.
4
EMB-driven glioblastoma multiforme progression via the MCT4/GPX3 axis: therapeutic inhibition by Ganxintriol A.
J Transl Med. 2025 Mar 4;23(1):272. doi: 10.1186/s12967-025-06290-z.
5
The subventricular zone structure, function and implications for neurological disease.
Genes Dis. 2024 Aug 26;12(3):101398. doi: 10.1016/j.gendis.2024.101398. eCollection 2025 May.
6
The role of lncRNAs in the interplay of signaling pathways and epigenetic mechanisms in glioma.
Epigenomics. 2025 Feb;17(2):125-140. doi: 10.1080/17501911.2024.2442297. Epub 2025 Jan 19.
7
Casein Kinase 2 Inhibitor, CX-4945, Induces Apoptosis and Restores Blood-Brain Barrier Homeostasis in In Vitro and In Vivo Models of Glioblastoma.
Cancers (Basel). 2024 Nov 24;16(23):3936. doi: 10.3390/cancers16233936.
8
Pan-Cancer Analysis of PTBP1 to Identify it as a Prognostic and Immunological Biomarker.
Cancer Control. 2024 Jan-Dec;31:10732748241302865. doi: 10.1177/10732748241302865.
9
hsa-miR-181a-5p inhibits glioblastoma development via the MAPK pathway: and study.
Oncol Res. 2024 Nov 13;32(12):1949-1958. doi: 10.32604/or.2024.051569. eCollection 2024.
10
Regulation of autophagy by non-coding RNAs in human glioblastoma.
Med Oncol. 2024 Oct 7;41(11):260. doi: 10.1007/s12032-024-02513-3.
本文引用的文献
1
mTOR: from growth signal integration to cancer, diabetes and ageing.
Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35. doi: 10.1038/nrm3025. Epub 2010 Dec 15.
2
North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme.
Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):468-75. doi: 10.1016/j.ijrobp.2010.05.064. Epub 2010 Sep 23.
3
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
J Neurooncol. 2011 Jun;103(2):325-32. doi: 10.1007/s11060-010-0390-7. Epub 2010 Sep 7.
4
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
Neuro Oncol. 2010 Dec;12(12):1300-10. doi: 10.1093/neuonc/noq099. Epub 2010 Aug 17.
5
A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas.
Cancer. 2010 Nov 15;116(22):5297-305. doi: 10.1002/cncr.25462.
6
Glioblastoma cancer stem cells: heterogeneity, microenvironment and related therapeutic strategies.
Cell Biochem Funct. 2010 Jul;28(5):343-51. doi: 10.1002/cbf.1666.
7
Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology.
Neuro Oncol. 2010 Jun;12(6):520-7. doi: 10.1093/neuonc/nop066. Epub 2010 Feb 8.
8
Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.
Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):347-53. doi: 10.1016/j.ijrobp.2010.01.070. Epub 2010 May 25.
9
mTOR signaling in glioblastoma: lessons learned from bench to bedside.
Neuro Oncol. 2010 Aug;12(8):882-9. doi: 10.1093/neuonc/noq052. Epub 2010 May 14.
10
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
J Clin Oncol. 2010 Jun 10;28(17):2817-23. doi: 10.1200/JCO.2009.26.3988. Epub 2010 May 10.
Zotero 插件